[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tauopathies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tauopathies":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,71,98,127,148,171],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100539444","early-phase-1-study-of-biodistribution-metabolism-excretion-and-brain-uptake11c-m503-100539444",false,"NCT06303921","Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503","Center Without Walls for Imaging Proteinopathies With PET (CW2IP2): Phase I Pilot Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-M503","Inclusion Criteria:\n\n* Patients in all cohorts will be male or female adults from 40 to 85 years of age.\n* Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures or Participants who are deemed unable to provide informed consent must have a designated study partner present for consent and to accompany them to study visits\n* Investigators will ask PD\u002FMSA\u002FPSP participants to agree to brain donation but this choice is not mandatory for participation in this study.\n* Diagnosis-specific inclusion criteria: Clinical diagnoses will be determined by consensus committee for diagnostic agreement (PD, MSA, PSP or Healthy Control)\n\nExclusion Criteria:\n\n* Females who are pregnant or breast feeding will be excluded, a urine pregnancy test will be performed in women of child-bearing potential prior to injection of 11C -M503, 11C-PiB or 18F-Florbetaben\n* Forms of parkinsonism other than PD, PSP and MSA as defined above\n* Major psychiatric disorder (e.g. schizophrenia or bipolar disorder) - major depressive disorder is allowed\n* History of significant or ongoing alcohol abuse or substance abuse or dependence based on medical record review or self-reported\n* Contraindications or inability to tolerate imaging, arterial line or IV placement or blood draw procedures in the opinion of an investigator or treating physician\n* Contraindication to MRI, such as non-compatible implanted medical device\n* Any current medical condition, illness, or disorder as assessed by medical record review and\u002For self-reported that is considered by a physician or investigator to be a condition that could compromise participant safety or successful participation in the study",true,"ALL","40 Years","85 Years",{"count":21,"type":22},70,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 11C-M503. The goal of this radiotracer is to quantify alpha-synuclein that is abnormally deposited in the brain of people with Parkinson's disease (PD). Investigators will compare uptake in participants with PD versus participants with multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), as well as non-Parkinsonism volunteers. This multicenter project funded by an NIH U19 grant, is centered at U Pennsylvania (Penn, Grant PI: Robert Mach) in collaboration with U Pittsburgh (Pitt) (non-clinical site) Yale U, U of California at San Francisco (UCSF) and Washington University in St. Louis (WU). The University of Pennsylvania will act as the sIRB for this multi-center human subjects project and participants will be recruited from all sites.",[28],"Tauopathies",[30,31,32],"Positron Emission Tomography (PET)","Brain MRI","Parkinson's disease (PD)","RECRUITING","2026-04-23",{"date":36,"type":37},"2026-04-24","ACTUAL",{"date":39,"type":37},"2024-02-16",{"date":41,"type":22},"2029-02",{"name":43,"class":44},"University of Pennsylvania","OTHER",3,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100522503","cw2ip2-imaging-and-diagnostic-assessments-100522503","NCT06083467","CW2IP2: Imaging and Diagnostic Assessments","Center Without Walls for Imaging Proteinopathies With PET (CW2IP2): Imaging and Diagnostic Assessments","Inclusion Criteria:\n\n* Participants: Patients in all cohorts will range from 40 to 85 yrs and will be both male and female.\n* Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures. Participants who are deemed unable to provide informed consent must have a designated Legally Authorized Representative(LAR) present for consent and a Study Partner to accompany them to study visits. The LAR and the Study Partner may be the same person.\n* Clinical diagnoses for each cohort will be determined by consensus committee for diagnostic agreement (PD, MSA, PSP, FTD or Healthy control)\n\nExclusion Criteria:\n\n* Females who are pregnant or breast feeding at the time of screening will be excluded\n* Forms of parkinsonism other than PD, PSP and MSA as defined above\n* Major psychiatric disorder (e.g. schizophrenia or bipolar disorder)\n* History of significant or ongoing alcohol abuse or substance abuse or dependence based on medical record review or self-reported\n* Contraindications or Inability to tolerate imaging, arterial line or IV placement or blood draw procedures in the opinion of an investigator or treating physician\n* Implanted medical device or other contraindication to MRI\n* Any current medical condition, illness, or disorder as assessed by medical record review and\u002For self-reported that is considered by a physician or investigator to be a condition that could compromise participant safety or successful participation in the study\n* Refusal to consent to brain donation (except for HC cohort). All non-HC participants must agree to postmortem brain donation..",{"count":54,"type":22},94,[56],"NA","This current protocol will provide the key data to help determine the specificity of our to-be-developed radiotracers by implementing a multi-site diagnostic assessment core and PET imaging of A-beta amyloid (may be completed at some sites as part of another protocol) that is commonly deposited in the brains of people with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP) or Frontotemporal Dementia (FTD) as well as healthy controls. This multicenter U19 grant is centered at U Pennsylvania (U Penn) (PI: Robert Mach) in collaboration with U Pittsburgh (Pitt), Yale University, U of California at San Francisco (UCSF) and Washington University in St. Louis (WU). U Penn will act as the single IRB of Record (sIRB) for this multi-center project and subjects will be recruited from all sites.",[28],[60,61],"Amyloid PET","Movement disorders","2026-01-06",{"date":64,"type":37},"2026-01-07",{"date":66,"type":37},"2023-07-20",{"date":68,"type":22},"2028-07-31",{"name":43,"class":44},1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":80,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},"100587778","early-phase-1-study-of-biodistribution-metabolism-excretion-and-brain-uptake-18f-jss20-183a-100587778","NCT06932809","Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A","Center Without Walls for Imaging Proteinopathies With PET (CW2IP2): Phase I Pilot Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 18F-JSS20-183A","Inclusion Criteria:\n\n1. Patients in all cohorts will be male or female adults from 40 to 85 years of age.\n2. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures or Participants who are deemed unable to provide informed consent must have a designated study partner present for consent and to accompany them to study visits.\n\nInvestigators will ask disease cohort participants to agree to brain donation, but this choice is not mandatory for participation in this study.\n\nDiagnosis-specific inclusion criteria: Clinical diagnoses will be determined by consensus committee (except AD and HC cohorts) for diagnostic agreement using video exams of each participant that are stored at WashU in a secured video repository with view-only access exclusively by secured virtual private network (VPN) connection. Video exam and screening assessments for PSP, CBS, MSA, PD, and FTLD may not be required to be repeated if they have been done within 6 months of enrollment, unless requested at the discretion of an investigator to document changes in clinical progression. A consensus committee will not be required to be repeated for participants who have already had a consensus committee diagnosis documented.\n\nExclusion Criteria:\n\n1. Females who are pregnant or breast feeding will be excluded, a urine pregnancy test will be performed in women of child-bearing potential prior to injection of 18F-JSS20-183A 11C-PiB or 18F-Florbetaben\n2. Forms of parkinsonism other than PSP-RS, and PD as defined above\n3. History of significant or ongoing alcohol abuse or substance abuse or dependence based on medical record review or self-reported\n4. Contraindications or inability to tolerate imaging, arterial line or IV placement or blood draw procedures in the opinion of an investigator or treating physician\n5. Contraindication to MRI, such as non-compatible implanted medical device\n6. Any current medical condition, illness, or disorder as assessed by medical record review and\u002For self-reported that is considered by a physician or investigator to be a condition that could compromise participant safety or successful participation in the study",{"count":79,"type":22},90,[25],"The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 18F-JSS20-183A. The goal of this radiotracer is to quantify 4Repeat Tau (4Rtau) protein that is abnormally deposited in the brain of people with a class of neurodegenerative diseases called tauopathies, such as Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), syndromes of genetic Frontotemporal Lobar Degeneration (genetic FTLD) as well as participants with Parkinson disease (PD), Alzheimer's Disease (AD) and healthy controls. This multicenter project funded by an NIH U19 grant, is centered at U Pennsylvania (Penn, Grant PI: Robert Mach) in collaboration with U Pittsburgh (Pitt), Yale U, U of California at San Francisco (UCSF) and Washington University in St. Louis (WUSTL). The University of Pennsylvania will act as the sIRB for this multi-center human subjects project and participants will be recruited from all sites.",[28],[30,31,84,85,86,87,88],"Parkinsons Disease (PD)","Alzheimers Disease (AD)","Progressive Supranuclear Palsy (PSP)","Corticobasal Syndrome (CBS)","Genetic Frontotemporal Lobar Degeneration (Genetic FTLD)","2025-12-19",{"date":91,"type":37},"2025-12-23",{"date":93,"type":37},"2025-05-09",{"date":95,"type":22},"2030-04",{"name":43,"class":44},2,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":16,"sex":17,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":108,"studyType":109,"phases":4,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":97},"100616514","18fnidf-pet-imaging-in-tau-related-diseases-100616514","NCT07306598","[18F]NIDF PET Imaging in Tau-related Diseases","Inclusion Criteria:\n\n1. Between 18 and 90 years old;\n2. No gender limitation;\n3. Clinical diagnositic rerults supported the diagnosis of neurodegeneration, and there was no evidence of other neurological diseases;\n4. Healthy participants or patients with probable Alzheimer's disease or with dementia due to other causes;\n5. Informed consent signed in person by the subject or his legal guardian or caregiver.\n\nExclusion Criteria:\n\n1. Has allergy to \\[18F\\]NIDF or any of its excipients;\n2. Incapable of providing written informed consent or lacking a legally authorized representative (LAR) to provide informed consent ;\n3. Unwilling or unable to undergo PET scans tracer injections;\n4. Any condition that, in the Investigator's opinion, could increase the risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection\u002Fanalysis of the data (e.g., renal or liver failure, advanced cancer);\n5. Received an experimental drug or device within 1 month (whose efficacy or safety is unclear);\n6. Have other serious neurological disorders, or gastrointestinal, cardiovascular, liver, kidney, blood system, tumor, endocrine, respiratory, immune deficiency, and other serious diseases;\n7. Women who are currently pregnant or breastfeeding.","18 Years","90 Years",{"count":107,"type":22},20,"7 Days","OBSERVATIONAL","In the field of diagnosing brain neurodegenerative diseases, it is now a well-established practice to inject positron-emitting tracers into the human body. These tracers bind to specific target proteins, allowing their distribution to be visualized via PET imaging. Currently, several research groups worldwide are engaged in developing and clinically validating their own tau imaging agents.\n\nThis clinical research project aims to visualize abnormal tau pathology in the living human brain using \\[18F\\]NIDF PET imaging. \\[18F\\]NIDF is a 2-arene-azaindole-based tracer that offers stronger binding affinity to tau neurofibrillary tangles and reduced non-specific\u002Foff-target binding compared to existing tau-PET imaging agents. The study primarily focuses on evaluating the safety and diagnostic efficacy of \\[18F\\]NIDF PET imaging in human subjects.",[112,113,28],"Neurodegenerative Disease","Alzheimer s Disease",[115,116,117,28],"PET\u002FCT","Alzheimer's disease","Tau pathologies","2025-12-14",{"date":120,"type":37},"2025-12-29",{"date":122,"type":37},"2025-11-01",{"date":124,"type":22},"2030-12-01",{"name":126,"class":44},"Tianjin Medical University",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":146,"leadSponsor":147,"locationsCount":70},"100518552","early-phase-1-study-of-biodistribution-metabolism-excretion-and-brain-uptake-of-11c-hy-2-15-100518552","NCT06032026","Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15","Center Without Walls for Imaging Proteinopathies With PET (CW2IP2): Phase I Pilot Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15","Inclusion Criteria:\n\n* The entire cohort will include men and women clinically diagnosed with MSA, PD, PSP or are healthy controls. A sub-set of these participants who undergo whole body scanning that will be used for analysis of biodistribution and dosimetry calculations.\n* Patients in all cohorts will be male or female adults from 40 to 80 years of age.\n* Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures or Participants who are deemed unable to provide informed consent must have a designated study partner present for consent and to accompany them to study visits\n* We will ask PD\u002FMSA\u002FPSP participants to agree to brain donation but this choice is not mandatory for participation in this study.\n* Diagnosis-specific inclusion criteria: Clinical diagnoses will be determined by consensus committee for diagnostic agreement (PD, MSA, PSP or Healthy Control)\n\nExclusion Criteria:\n\n* Females who are pregnant or breast feeding will be excluded, a urine pregnancy test will be performed in women of child-bearing potential prior to injection of 11C HY-2-15, 11C-PiB or Florbetaben\n* Forms of parkinsonism other than PD, PSP and MSA as defined above\n* Major psychiatric disorder (e.g. schizophrenia or bipolar disorder) - major depressive disorder is allowed\n* History of significant or ongoing alcohol abuse or substance abuse or dependence based on medical record review or self-reported\n* Contraindications or inability to tolerate imaging, arterial line or IV placement or blood draw procedures in the opinion of an investigator or treating physician\n* Contraindication to MRI, such as non-compatible implanted medical device\n* PSP and MSA subjects will be excluded if they have a history of any prior positive ß-amyloid PET scan or positive CSF AD biomarkers.\n* Any current medical condition, illness, or disorder as assessed by medical record review and\u002For self-reported that is considered by a physician or investigator to be a condition that could compromise participant safety or successful participation in the study","80 Years",{"count":21,"type":22},[25],"The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 11C HY-2-15. The goal of this radiotracer is to quantify alpha-synuclein that is abnormally deposited in the brain of people with Multiple System Atrophy (MSA). The investigators will compare uptake in people with MSA with people with Parkinson disease (PD) and progressive supranuclear palsy (PSP) as well as healthy volunteers. This multicenter project funded by an NIH U19 grant, is centered at U Pennsylvania (Penn, Grant PI: Robert Mach) in collaboration with U Pittsburgh (Pitt) (not a clinical site), Yale U, U of California at San Francisco (UCSF) and Washington University in St. Louis (WU). The University of Pennsylvania will act as the sIRB for this multi-center human subjects project and participants will be recruited from all sites.",[28],[140,30,141],"Alpha synuclein","brain MRI","2025-11-18",{"date":144,"type":37},"2025-11-19",{"date":66,"type":37},{"date":68,"type":22},{"name":43,"class":44},{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":16,"sex":17,"minAge":104,"maxAge":134,"enrollmentInfo":154,"targetDuration":108,"studyType":109,"phases":4,"briefSummary":156,"conditions":157,"keywords":160,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":97},"100569187","tau-petct-in-various-tau-related-disease-patients-100569187","NCT06690983","Tau PET\u002FCT in Various Tau-Related Disease Patients","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Tau PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":155,"type":22},500,"To evaluate the potential usefulness of 18F-S16\u002FT807 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.",[28,158,159],"Neurodegenerative Diseases","Neurodegeneration",[115,161,162],"MRI","Tau","2025-02-07",{"date":165,"type":37},"2025-02-11",{"date":167,"type":37},"2018-08-01",{"date":169,"type":22},"2027-12-01",{"name":126,"class":44},{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":17,"minAge":179,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":182,"conditions":183,"keywords":200,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":70},"100561944","neurodegenerative-diseases-progression-markers-markers-ndd-100561944","NCT06596746","Neurodegenerative Diseases Progression Markers (MARKERS-NDD)","Neurodegenerative Diseases Progression Markers (MARKERS-NDD): a Real-world Data Longitudinal Prospective Study","MARKERS-NDD","Inclusion Criteria:\n\n* Patients with diagnosis of Parkinson's Disease, Parkinsonism and Movement Disorders\n\n  * Patients with diagnosis of Parkinson's Disease\n\n    * Diagnosis of Parkinson's Disease according to the United Kingdom (UK) Parkinson's Disease Society Brain Bank\n  * Diagnosis of Movement Disorder not related to Parkinson's Disease\n\n    * Diagnosis of Multiple System Atrophy (MSA) in accordance with Second Consensus Statement on Diagnosis of Multiple System Atrophy;\n    * Diagnosis of Progressive Supranuclear Palsy according to Movement Disorder Society for Diagnosis of Progressive Supranuclear Palsy;\n    * Diagnosis of Essential Tremor\n    * Willing to participate in the study, understand the procedures and sign the informed consent.\n* Patients affected by cognitive impairment (CI) and dementia\n\n  * Diagnosis of probable:\n\n    * Lewy Body Dementia\n    * Alzheimer's Disease\n    * Mild Cognitive Decline\n    * Subjective memory complaints\n    * Willing to participate in the study, understand the procedures and sign the informed consent.\n\nExclusion Criteria:\n\n* There are no restrictions for participation in the study based on age, severity of illness or presence of cognitive impairment, as long as the person is able to complete the research assessments.","10 Years",{"count":181,"type":22},600,"MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal clinical practice. Data collected from clinical evaluations, movement analysis, brain imaging, neuropsychological and electroencephalographic assessments, blood chemistry tests will be analysed to carry out statistical investigations and predictive analyses, also using artificial intelligence systems, which allow the identification of new early markers of diagnosis and prognosis of neurodegenerative diseases.",[158,184,185,186,187,28,188,189,190,191,192,193,194,195,196,197,198,199],"Parkinson Disease","Synucleinopathies","Lewy Body Disease","Multiple System Atrophy","Alzheimer Disease","Corticobasal Degeneration","Supranuclear Palsy, Progressive","Atypical Parkinsonism","TDP-43 Proteinopathies","Amyotrophic Lateral Sclerosis","Frontotemporal Lobar Degeneration","Movement Disorders","Cognitive Impairment","Dementia","Iron Overload","Neurodegeneration With Brain Iron Accumulation (NBIA)",[158,201,202,203,204,205,206,207,208,209,210,211,212,213,214],"Markers","Gait analysis","Wearable inertial sensors","IMU","Artificial intelligence","AI-Video gait analysis","Handwriting analysis","Voice-based artificial intelligence systems","imaging","multimodal analysis","electroencephalogram","cortical activity","gut microbiota","laboratory blood chemistry parameters","2024-09-11",{"date":217,"type":37},"2024-09-19",{"date":219,"type":22},"2024-09-09",{"date":221,"type":22},"2034-09-09",{"name":223,"class":224},"Casa di Cura San Raffaele Cassino","NETWORK"]